Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances

Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical ...

Pacira BioSciences: Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences ...

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- ...
PharmiWeb

Encoded Therapeutics Highlights Progress in Dravet Syndrome Program and Pipeline Ahead of Company Presentation at 44th Annual J.P. Morgan Healthcare Conference

Positive interim efficacy data in 2025 underscore potential of ETX101 as a one-time, disease-modifying medicine for Dravet syndrome –– Internal GMP manufacturing capable of supporting pivotal trial ...

Pentec Health Acquires Hartley Medical, Advancing Intrathecal Pain and Implanted Pump Management

Together, Pentec and Hartley bring an integrated approach to intrathecal therapy, spanning medication preparation, clinical care, and administrative support. The combined model is intended to support ...

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late ...